Galectin Therapeutics (GALT) Price & Analysis

Compare

662 Followers

GALT Stock Chart & Stats

$5.71

-$0.06(-5.00%)

At close: Jan 08 4:00 PM EST

$5.71

-$0.06(-5.00%)

Day’s Range― - ―

52-Week Range$0.94 - $7.13

Previous CloseN/A

Volume135.57K

Average Volume (3M)341.94K

Market Cap

$261.14M

Enterprise Value$242.83M

Total Cash (Recent Filing)$11.53M

Total Debt (Recent Filing)$122.31M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Mar 26, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding64,479,210

10 Day Avg. Volume287,288

30 Day Avg. Volume341,945

Financial Highlights & Ratios

PEG Ratio-0.63

Price to Book (P/B)-0.78

Price to Sales (P/S)0.00

P/FCF Ratio-1.92

Enterprise Value/Market Cap0.93

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-11.04K

Enterprise Value/Ebitda-8.05

Forecast

1Y Price Target

$11.00

Price Target Upside92.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Funding And Financial StabilityA new $10 million line of credit is expected to help fund current expenditures into 1H27, alleviating concerns of a financial overhang.

Regulatory ClarityFDA feedback clarifies potential patient population and diagnostics that can be used in planned Phase 3.

Therapeutic AdvancementsBelapectin's positive impact on the incidence of new esophageal varices and its anti-fibrotic activity in advanced MASH patients were highlighted.

Bears Say

Clinical Timeline DelaysThis morning's negative stock reaction is based on perceived delays to clinical timelines; however, additional FDA interactions should only minimally delay MASH program timeline, in the analyst's opinion.

Galectin Therapeutics News

Galectin Therapeutics provides regulatory update following FDA written response

Galectin Therapeutics (GALT) announced that the U.S. Food and Drug Administration, FDA, has provided a written response, and...

12d ago

GALT

Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright

H.C. Wainwright analyst Matthew Keller raised the firm’s price target on Galectin Therapeutics (GALT) to $11 from $6...

14d ago

GALT

Galectin Advances Belapectin Program, Secures New Insider Financing

Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, Galectin Therapeutics reported that the...

12d ago

GALT

Galectin Therapeutics Holds 2025 Annual Stockholders Meeting

Galectin Therapeutics ( ($GALT) ) just unveiled an update. At the 2025 Annual Meeting of Stockholders on December...

23d ago

GALT

Galectin Therapeutics Reveals Promising NAVIGATE Trial Results

Galectin Therapeutics ( ($GALT) ) just unveiled an announcement. On December 3, 2025, Galectin Therapeutics presented compelling results...

28d ago

GALT

Galectin Therapeutics Reports Q3 2025 Financials

Galectin Therapeutics (GALT) ( ($GALT) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

GALT

Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment

Matthew Keller, an analyst from H.C. Wainwright, reiterated the Buy rating on Galectin Therapeutics. The associated price target...

2M ago

GALT

Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year

“The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue...

2M ago

GALT

Galectin Therapeutics presents NAVIGATE trial results at AASLD

Galectin Therapeutics (GALT) presented a poster and will deliver an oral presentation of the NAVIGATE study analysis at...

2M ago

GALT

Galectin Therapeutics Presents Promising NAVIGATE Trial Results

An announcement from Galectin Therapeutics ( ($GALT) ) is now available. On November 10, 2025, Galectin Therapeutics announced...

2M ago

GALT

Galectin Therapeutics Highlights Promising Belapectin Results

An update from Galectin Therapeutics ( ($GALT) ) is now available. On September 8, 2025, Galectin Therapeutics updated...

4M ago

GALT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Enovix (ENVX) 6.97% +5.59,...

4M ago

ING

AMPY

Galectin Therapeutics Reports Reduced Losses in Q2 2025

Galectin Therapeutics (GALT) ( ($GALT) ) has released its Q2 earnings. Here is a breakdown of the information...

5M ago

GALT

Optimistic Buy Rating for Galectin Therapeutics Driven by Belapectin’s Potential in Treating Liver Cirrhosis and Strategic Focus

In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics, with...

5M ago

GALT

GALT FAQ

What was Galectin Therapeutics Inc’s price range in the past 12 months?

Galectin Therapeutics Inc lowest stock price was $0.94 and its highest was $7.13 in the past 12 months.

What is Galectin Therapeutics Inc’s market cap?

Galectin Therapeutics Inc’s market cap is $261.14M.

When is Galectin Therapeutics Inc’s upcoming earnings report date?

Galectin Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 85 days.

How were Galectin Therapeutics Inc’s earnings last quarter?

Galectin Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.02.

Is Galectin Therapeutics Inc overvalued?

According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Galectin Therapeutics Inc pay dividends?

Galectin Therapeutics Inc does not currently pay dividends.

What is Galectin Therapeutics Inc’s EPS estimate?

Galectin Therapeutics Inc’s EPS estimate is -0.1.

How many shares outstanding does Galectin Therapeutics Inc have?

Galectin Therapeutics Inc has 64,479,210 shares outstanding.

What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?

Galectin Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -0.362%.

Which hedge fund is a major shareholder of Galectin Therapeutics Inc?

Currently, no hedge funds are holding shares in GALT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Galectin Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-43.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to improve the lives of patients with chronic liver diseases and cancer. The company operates in the biotechnology and pharmaceutical sectors, with a core emphasis on discovering and developing drugs targeting galectin proteins, which are critical in numerous disease processes. Galectin Therapeutics aims to leverage its proprietary technology to create novel treatments, primarily targeting fibrosis and cancer.

Galectin Therapeutics (GALT) Earnings & Revenues

Historic Earnings Reports

GALT Stock 12 Month Forecast

Average Price Target

$11.00

▲(92.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,5.932307692307692,6.354615384615385,6.776923076923077,7.199230769230769,7.621538461538462,8.043846153846154,8.466153846153846,8.888461538461538,9.310769230769232,9.733076923076922,10.155384615384616,10.577692307692308,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,5.932307692307692,6.354615384615385,6.776923076923077,7.199230769230769,7.621538461538462,8.043846153846154,8.466153846153846,8.888461538461538,9.310769230769232,9.733076923076922,10.155384615384616,10.577692307692308,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,5.932307692307692,6.354615384615385,6.776923076923077,7.199230769230769,7.621538461538462,8.043846153846154,8.466153846153846,8.888461538461538,9.310769230769232,9.733076923076922,10.155384615384616,10.577692307692308,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >